Home » Illumina Launches TruSight Tumor 170
Illumina Launches TruSight Tumor 170
Illumina has launched TruSight Tumor 170, which is a 170 gene sequencing solution to support the evolution of the tumor-profiling paradigm from a series of single-gene tests to a multi-analyte approach.
This assay is designed to support limited nucleic acid input from formalin-fixed, paraffin-embedded samples and facilitates efficient evaluation of biomarkers.
The device will begin production in early 2017. — Cynthia Jessup
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May